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Brief Definit ive Report
T cell acute lymphoblastic leukemia (T-ALL) 
is a heterogeneous disease in which genetic 
lesions coordinately affect cell proliferation, 
differentiation, and survival of thymocytes 
(Ferrando, 2009; Paganin and Ferrando, 
2011). T-ALL accounts for 15% of pediatric 
and 25% of adult ALL cases. Importantly, 
significant differences in outcome are pres-
ent between pediatric and adult T-ALL (Pui 
et al., 2008). Thus, although >70% of children 
achieve long lasting complete remissions, only 
50% of adult T-ALL patients are currently cured. 
In addition, pediatric and adult T-ALLs show 
marked differences in the frequency of spe-
cific genetic lesions. For example, chromosomal 
translocation and aberrant expression of the 
TAL1 and TLX3 oncogenes are highly prev-
alent in children, but rare in adults. In con-
trast, translocations activating TLX1 are rarely 
found in pediatric leukemias but represent 
one third of adult T-ALL cases (Ferrando et al., 
2002, 2004).
RESULTS AND DISCUSSION
To gain more insight in the genetic and on-
cogenic mechanisms driving adult T-ALL, we 
analyzed a series of 57 T-ALL samples treated 
in the Eastern Cooperative Oncology Group 
(ECOG) E2993 protocol (Marks et al., 2009) 
using gene expression oligonucleotide micro-
arrays. Unsupervised analysis and consensus 
clustering of microarray gene expression data 
revealed the presence of 2 stable gene expres-
sion clusters (Cluster I and II) encompassing 
approximately half of the tumor samples ana-
lyzed each (Fig. 1 A). Supervised analysis 
demonstrated that each of these two groups 
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Early immature T cell acute lymphoblastic leukemias (T-ALLs) account for 5–10% of 
pediatric T-ALLs and are associated with poor prognosis. However, the genetic defects that 
drive the biology of these tumors remain largely unknown. In this study, analysis of micro-
array gene expression signatures in adult T-ALL demonstrated a high prevalence of early 
immature leukemias and revealed a close relationship between these tumors and myeloid 
leukemias. Many adult immature T-ALLs harbored mutations in myeloid-specific oncogenes 
and tumor suppressors including IDH1, IDH2, DNMT3A, FLT3, and NRAS. Moreover, we 
identified ETV6 mutations as a novel genetic lesion uniquely present in immature adult T-ALL. 
Our results demonstrate that early immature adult T-ALL represents a heterogeneous 
category of leukemias characterized by the presence of overlapping myeloid and T-ALL 
characteristics, and highlight the potential role of ETV6 mutations in these tumors.
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stage of thymocyte development 
(Ferrando et al., 2002). In contrast, early 
cortical T-ALLs are characteristically 
CD1a, CD4, and CD8 positive and 
are frequently associated with translo-
cations inducing aberrant expression of 
the TLX1 and TLX3 homeobox tran-
scription factor oncogenes (Ferrando 
et al., 2002). Finally, late cortical thy-
mocyte T-ALLs show expression of 
CD4, CD8, and CD3 and activation 
of the TAL1 transcription factor on-
cogene (Ferrando et al., 2002; Soulier 
et al., 2005; Homminga et al., 2011). GSEA of genes asso-
ciated with these pediatric molecular groups of T-ALL 
(Ferrando et al., 2002) against the two clusters of adult 
T-ALLs identified in our series showed a highly significant 
enrichment of LYL1/immature T-ALL–associated genes in 
cluster I, whereas cluster II was associated with TLX1/early 
cortical and TAL1/late cortical T-ALL signatures (Fig. 1 C). 
Consistently, all TLX1 (n = 5) and TLX3 (n = 5), and 8/10 
TAL1 high/LMO1/LMO2, expression leukemias in this 
series were included in cluster II.
Notably, transcriptionally defined early immature adult 
T-ALLs in cluster I showed an early arrest in T cell develop-
ment and were characterized by the expression of cytoplas-
mic CD3 together with early hematopoietic markers such as 
CD34 (22/29, 76%) and CD133 (14/29, 48%) and myeloid-
associated antigens such as CD13 (19/29, 65%), CD33 
(16/29, 55%), and CD11b (16/29, 55%; Table S1). How-
ever, despite these common features, we could still identify 
three different immunophenotype categories within this 
group based on the expression of CD5. Thus, 10/29 cases 
(34%) showed complete absence of surface CD5 expression, 
16/29 (55%) showed low levels of surface CD5 expression, 
and 3/29 (11%) were strongly CD5 positive (Table S1). 
is characterized by a distinct gene expression program en-
compassing 365 differentially expressed unique genes (fold 
change >1.5; P < 0.0001; Fig. 1 B). Similar results were 
obtained in an independent validation set of 30 adult 
T-ALLs (Chiaretti et al., 2004). Thus, consensus cluster-
ing identified two robust clusters encompassing 12 and 18 
samples, respectively in this series (Fig. S1). Moreover, cross 
analysis of clusters identified in the discovery and validation 
datasets using gene set enrichment analysis (GSEA) demon-
strated a high level of enrichment in the expression signa-
tures associated with clusters I and II in our discovery series 
in the clusters identified in this second dataset and vice 
versa, a high level of enrichment of a high level of enrich-
ment in differentially expressed genes between clusters 
I and II in our validation series in the clusters identified in 
this our original dataset (Fig. S1).
Gene expression profiling of pediatric T-ALLs has de-
fined distinct molecular subgroups associated with the activa-
tion of specific transcription factor oncogenes and unique 
gene expression signatures reflecting a distinct arrest during 
T cell development (Ferrando et al., 2002, 2004; Soulier 
et al., 2005; Homminga et al., 2011). Early immature/LYL1-
positive T-ALLs show an early block at the double-negative 
Figure 1. Gene expression profiling iden-
tifies high prevalence of early immature 
leukemias in adult T-ALL. (A) Consensus 
clustering of microarray gene expression data 
of 57 adult T-ALL samples. (B) Top 50 differ-
entially expressed genes between adult T-ALL 
cluster I and cluster II samples. Genes in the 
heat map are shown in rows and each indi-
vidual sample is shown in one column. The 
scale bar shows color-coded differential ex-
pression from the mean in standard deviation 
units with red indicating higher levels and 
blue lower levels of expression. (C) GSEA anal-
ysis of early immature/LYL1-positive, early 
cortical/TLX1-positive, and late cortical/TAL1-
positive associated genes in the gene expres-
sion clusters I and II identified in adult  
T-ALL. (D) GSEA of genes associated with  
pediatric ETP-T-ALLs in adult T-ALL gene  
expression clusters.
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used a similar approach to analyze the relationship of early 
immature T-ALLs with other hematopoietic lineages and 
progenitor populations (Novershtern et al., 2011). Surpris-
ingly, this analysis revealed a significant enrichment of 
genes up-regulated in long-term hematopoietic stem cells 
(Fig. 2 B) and in granulocyte-monocyte progenitors (Fig. 2 C) 
in this group. These results, together with the high preva-
lence of expression of immature (CD34, CD133) and 
myeloid (CD13, CD33, and CD11b) surface markers in 
these leukemias (Table S1) made us consider the possibility 
that early immature adult T-ALL tumors may be tran-
scriptionally and genetically related to acute myeloid leu-
kemias (AMLs).
To test this hypothesis, we analyzed the enrichment of 
lymphoid and myeloid leukemia gene expression signatures 
(Golub et al., 1999) in immature adult T-ALLs. This analysis 
revealed a highly significant enrichment of AML-associated 
transcripts in the early immature T-ALL cluster I group, 
whereas ALL associated transcripts were enriched in the 
T-ALL cluster II samples (Fig. 2, D and E). Based on this ob-
servation, we hypothesized that myeloid-specific genetic 
alterations might be uniquely present in immature adult 
T-ALLs. Strikingly, mutation analysis of AML oncogenes 
and tumor suppressor genes revealed the presence of myeloid 
mutations targeting IDH1, IDH2, DNMT3A, FLT3, and 
NRAS in 14/29 (48%) of immature adult T-ALL cases, 
whereas only 1/28 (3.5%) of all other adult T-ALLs showed 
a mutation in NRAS (P = 0.0001; Fig. 2 F and Table S2). In 
addition, immature adult T-ALL samples showed a lower 
Importantly, weak expression of CD5 in immature pediatric 
T-ALL leukemias has recently been associated with a gene 
expression program resembling early T cell progenitors and 
defines a group of childhood T-ALLs with poor prognosis 
(Coustan-Smith et al., 2009). To test the relationship of adult 
T-ALLs with early T cell precursor (ETP) pediatric T-ALLs, 
we performed GSEA of adult T-ALL clusters I and II using a 
gene set of ETP-T-ALL–associated transcripts (Coustan-
Smith et al., 2009). This analysis showed a high level of 
enrichment of transcripts associated with this poor prog-
nostic pediatric T-ALL group in adult immature/cluster I 
T-ALLs (Fig. 1 D).
To explore the relationship between the genetic pro-
gram associated with adult early immature T-ALLs and normal 
thymocytes, we performed GSEA analysis of gene expres-
sion signatures associated with distinct human thymocyte 
subsets including early double-negative (CD34+, CD1a, 
CD4, CD8), late double-negative (CD34+, CD1a+, CD4, 
CD8), immature single-positive (CD4+, CD8, CD3), early 
double-positive (CD4+, CD8+, CD3), late double-positive 
(CD4+, CD8+, CD3+), mature CD4 single-positive (CD4+, 
CD8, CD3+), and mature CD8 single-positive (CD4, 
CD8+, CD3+) cells. This analysis demonstrated a signifi-
cant enrichment of genes characteristic for the earliest 
double-negative (CD34+, CD1a, CD4, CD8) T cell 
progenitors in the early immature T-ALL group (Fig. 2 A). 
Notably, early double-negative thymocytes are not yet 
committed to T cell development and retain multilineage 
potential (Bhandoola and Sambandam, 2006). Therefore, we 
Figure 2. Myeloid and stem cell features of immature adult T-ALL. (A–C) GSEA of transcripts significantly up-regulated in early immature adult  
T-ALL in gene expression signatures obtained from human early double negative thymocytes (CD34+CD1aCD4CD8; A) against all other thymocyte 
groups, long term hematopoietic stem cells (LT-HSC; B), and granulocyte-monocyte progenitors (GMP; C) against all other hematopoietic populations.  
(D and E) GSEA of AML- (D) or ALL-associated (E) transcripts in early immature (cluster I) versus other (cluster II) adult T-ALLs. (F) Differential distribution 
of myeloid-specific lesions in immature (cluster I) versus other (cluster II) adult T-ALLs.
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prevalence of prototypical T-ALL genetic 
alterations such as activating mutations in 
the IL7R gene (1/29 [3.5%] immature 
adult T-ALLs vs. 6/28 [21.5%] of all 
other adult T-ALL samples; P < 0.05) 
and mutations in NOTCH1 and FBXW7 
activating the NOTCH-signaling path-
way (12/29 [41%] immature adult 
T-ALLs vs. 26/28 [93%] of all other adult 
T-ALLs; P < 0.05; Table S2). Notably, 
myeloid-specific gene alterations and 
mutations activating IL7R or NOTCH 
signaling were overlapping in 7/29 (24%) 
of all immature adult T-ALLs (Table S2). 
Overall, these results show that early 
immature adult T-ALLs are a gray zone 
leukemia category characterized by the 
Figure 3. ETV6 mutations in early immature 
adult T-ALL. (A) Schematic representation of  
the structure of the ETV6 protein. The N-terminal 
pointed (PNT) homodimerization domain  
and the C-terminal DNA-binding domain  
(ETS-domain) are indicated. ETV6 mutations  
identified in primary adult T-ALL samples are 
shown. Filled circles represent frameshift muta-
tions, whereas the splice acceptor mutation in  
the exon 8 splice acceptor sequence is depicted  
as an open circle. (B and C) Representative DNA 
sequencing chromatograms of paired diagnosis 
and remission genomic T-ALL DNA samples  
showing a somatic frameshift mutation in exon  
6 (B) and a splice acceptor mutation in exon 8  
of ETV6 (C). (D) Sequence analysis of paired  
ETV6 genomic DNA and cDNA shows  
biallelic expression of wild-type and mutant  
ETV6 transcripts.
Table 1. ETV6 mutations in early immature adult T-ALL
ETV6 mutations T-ALL specific lesions Myeloid specific lesions
Sample ID Exon Predicted 
amino acid 
change
Homozygous/ 
heterozygous
Somatic/ 
germline
NOTCH1 FBXW7 NRAS IDH2 DNMT3A
3 3 S105fs het NA MUT WT MUT WT WT
5 8 R417fs het somatic MUT WT WT WT WT
18 3 Y103fs homo (LOH) somatic MUT WT WT WT WT
24 4 S130fs het somatic MUT WT WT WT WT
27 2 P50fs het NA MUT WT MUT WT WT
58 5 L178fs het NA WT WT WT MUT MUT
59 5 V158fs het NA MUT WT WT WT MUT
60 3 V66fs het NA WT WT WT WT WT
61 6 V345fs het somatic MUT WT WT WT WT
62 6 N356fs homo (LOH) NA MUT WT WT WT WT
LOH, loss of heterozygosity; NA, not available
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broader role of ETV6 in the pathogenesis of T-ALL, we 
screened all coding exons of ETV6 for the presence of 
somatic mutations in an extended series of adult leukemia 
cases. This analysis revealed the presence of ETV6 muta-
tions in 10 out of 82 (12%) adult T-ALL samples analyzed 
(Fig. 3, A–C; Table 1).  Strikingly, ETV6 mutations were 
exclusively found in early immature adult T-ALLs with ex-
pression of the early hematopoietic marker CD34, cytoplas-
mic CD3, and the myeloid-associated antigen CD33 in the 
absence of CD4 and CD8 (Table S3). The 
overall incidence of ETV6 mutations in imma-
ture adult T-ALL in this series was 10 out of 41 
(24%). In seven cases, ETV6 mutations corre-
sponded to frameshift insertions or deletions 
in the N-terminal part of the protein, whereas 
the three remaining alleles corresponded to 
C-terminal truncating alleles (2 frameshift in-
sertions and deletions and an exon 8 splice 
acceptor site mutation; Fig. 3 A). Analysis of 
bone marrow remission genomic DNA con-
firmed the somatic origin of ETV6 mutations 
(three frameshift and one splice site) in each of 
the four patient samples with available material 
(Fig. 3, B and C; Table 1). ETV6 mutations 
found in T-ALL were heterozygous in 8 out of 
presence of overlapping myeloid and T-lymphoid immuno-
phenotypic features and genetic alterations.
Notably, a similar cooccurrence of both T lymphoid and 
myeloid characteristics has been previously documented in 
rare leukemias harboring the translocation t(8;12)(q13;p13), 
which results in the fusion of the ETV6 tumor suppressor 
and the NCOA2 gene (Strehl et al., 2008; Homminga et al., 
2011). Given the prominent role of ETV6 in hematopoietic 
stem cell homeostasis (Hock et al., 2004) and to test a possible 
Figure 4. Functional analysis of truncating ETV6 
mutant alleles. (A and B) Western blot analysis of FLAG-
tagged N-terminal (Y103fs, S105fs) (A) and C-terminal 
(V345fs, N356fs) (B) ETV6 mutants expressed in HEK293T 
cells. The FLAG epitope was introduced in the C terminus 
of the N-terminal Y103fs and S105fs mutants and in the 
N terminus of the C-terminal ETV6 V345fs and N356fs 
mutants. Blots were probed with anti-FLAG or anti-
GAPDH as loading control. (C) Lysates from primary adult 
T-ALL samples harboring a heterozygous C-terminal 
(V345fs, #61) and a homozygous N-terminal 
(Y103fs,#18) ETV6 mutation were analyzed by Western 
blot. Wild-type ETV6 proteins are detected as 50 and 57 kD 
anti-ETV6 immunoreactive bands and anti-GAPDH as 
loading control. (D) Effects of ETV6 mutant alleles in the 
activity an ETV6-responsive reporter plasmid (pGL2-
754TR). Luciferase activity is shown relative to empty 
vector and normalized using an internal control plasmid 
expressing Renilla luciferase. Experiments were per-
formed in triplicate and repeated at least twice. (E) Lucif-
erase assay analyzing the effects of increasing amounts 
(indicated by wedges) of C-terminal (V345fs) and  
N-terminal (S105fs) ETV6 mutants on the activity of 
wild-type ETV6. Experiments were performed in triplicate 
and repeated at least twice. (F) Supervised analysis of 
ETV6 mutant versus ETV6 wild-type gene expression sig-
natures in early immature adult T-ALLs (P < 0.001). Top 
50 differentially expressed genes are shown. Genes in the 
heat map are shown in rows, each individual sample is 
shown in one column. The scale bar shows color-coded 
differential expression from the mean in standard devia-
tion units, with red indicating higher levels and blue 
lower levels of expression.
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PNT domain and retaining the DNA-binding domain 
(Fig. 4 A). C-terminal ETV6 truncating mutations (V345fs, 
N356fs) resulted in the expression of C-terminal truncated 
polypeptides (42 and 44 kD, respectively; Fig. 4 B). Consis-
tently, Western blot analysis of a primary patient sample har-
boring a homozygous N-terminal truncating mutation 
detected the presence of shorter mutant ETV6 isoforms 
(23 and 28 kD; Fig. 4 C), whereas analysis of a sample with a 
heterozygous C-terminal mutation revealed the expression of 
both wild-type (50 and 57 kD) and truncated (42 kD) ETV6 
proteins (Fig. 4 C).
To elucidate the functional consequences of ETV6 alter-
ations, we performed luciferase reporter assays using an 
ETV6-responsive reporter construct (pGL2-754TR) derived 
from the stromelysin-1 gene (Fenrick et al., 2000). In line 
with the role of ETV6 as transcriptional repressor, expression 
of wild-type ETV6 strongly decreased luciferase activity 
(Fig. 4 D). In contrast, C-terminal (V345fs; N356fs) and 
N-terminal (Y103fs; S105fs) ETV6 mutants were function-
ally inactive with no transcriptional repression activity 
(Fig. 4 D). Moreover, expression of C-terminal (V345fs) and 
N-terminal (S105fs) ETV6 mutants abolished the transre-
pression effects of wild-type ETV6 (Fig. 4 E), suggesting that 
10 cases (80%) with two patient samples showing copy 
neutral loss of heterozygosity resulting in homozygous 
N-terminal and C-terminal truncating alleles (Table 1). 
RT-PCR analysis confirmed expression of the remaining 
wild-type ETV6 allele in heterozygous ETV6 mutant adult 
T-ALL samples (Fig. 3 D). In addition, and in contrast with 
the lower incidence of NOTCH1 mutations present in the 
immature group, 8/10 (80%) of ETV6 mutant T-ALL cases 
showed mutations in NOTCH1 (Table 1), suggesting a 
specific interaction between the oncogenic programs acti-
vated by NOTCH1 and mutational loss of ETV6 in the patho-
genesis of adult immature T cell lymphoblastic leukemia.
The ETV6 tumor suppressor gene is frequently translo-
cated in lymphoid and myeloid hematopoietic tumors and 
encodes a transcriptional repressor with an N-terminal 
pointed (PNT) homodimerization domain and a C-terminal 
ETS DNA-binding domain (Bohlander, 2005). Transfection 
of plasmids driving the expression of N-terminal truncating 
ETV6 mutations (Y103fs, S105fs) found in adult T-ALL 
resulted in the activation of the M208 and M240 internal 
translation initiation sites (Barjesteh van Waalwijk van Doorn-
Khosrovani et al., 2005) and the expression of N-terminal 
truncated protein products (23 and 28 kD) devoid of the 
Figure 5. Transcriptional program regulated by ETV6 in T-ALL. (A) RT-PCR (top) and Western blot (bottom) analysis of ETV6 expression in LOUCY 
cells expressing control siRNA or one of two ETV6-specific siRNAs. (B) GSEA of the early immature ETV6 mutant T-ALL–associated transcripts in control 
siRNA versus ETV6 knockdown LOUCY cells. Heatmap of genes up-regulated in early immature ETV6 mutant T-ALL most differentially expressed in control 
siRNA versus ETV6 knockdown LOUCY cells. The myeloid marker CD33 and genes involved in leukemia development and stem cell homeostasis are shown 
in red. Genes in the heat map are shown in rows and each individual sample is shown in one column. The scale bar shows color-coded differential  
expression from the mean in standard deviation units, with red indicating higher levels and blue lower levels of expression.
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were then labeled with fluorophore-conjugated monoclonal antibodies 
against CD34 (CD34-APC) and CD1a (CD1-PE; BD). Early double nega-
tive thymocytes (CD34+CD1aCD3CD4CD8) and late double nega-
tive thymocytes (CD34+CD1a+CD3CD4CD8) were isolated by FACS. 
Immature single-positive thymocytes (CD4+CD8CD3), were isolated by 
FACS after immunomagnetic depletion of total thymocytes with the CD3 
MicroBead kit (Miltenyi Biotec) and immunostaining with CD4-PE (BD) 
and CD34-FITC antibodies. Early double-positive cells (CD4+CD8+CD3) 
were isolated by FACS from CD3 immunodepleted cells after staining 
with CD4-PE and CD8-FITC (BD) antibodies. Late double-positive 
(CD4+CD8+CD3+) and mature single-positive CD4 (CD4+CD3+) and 
CD8 (CD8+CD3+) thymocytes were FACS after triple immunolabeling 
with CD4-PE, CD8-FITC, and CD3-APC (BD) antibodies. Cell sorting 
was performed with a FACSDiva cell sorter (BD), and the purity of all sorted 
populations was >95%.
Microarray gene expression profiling of normal T cell subsets and 
primary adult T-ALL samples. RNA isolation from sorted subsets of 
human thymocytes was performed in triplicate using the RNeasy Micro kit 
(QIAGEN) according to manufacturer’s protocol. Next, 10 ng of RNA 
from each T cell subset was amplified using the Ovation PicoSL WTA 
System (NuGen), labeled by the Encore BiotinIL Module (NuGen), and 
hybridized to the HumanHT-12 v4 Expression BeadChip (Illumina) ac-
cording to manufacturer’s protocol. Similarly, RNA isolation from lympho-
blast obtained from adult T-ALL patient samples was achieved using the 
RNeasy plus mini kit (QIAGEN) according to manufacturer’s protocol. 
Next, 500 ng of RNA was amplified and biotinylated using the TotalPrep 
RNA Amplification kit (Invitrogen) and hybridized to the HumanHT-12 v4 
Expression BeadChip (Illumina).
Gene expression profiling data from 57 adult T-ALL patients and nor-
mal T cell subsets were normalized using quantile normalization without 
background subtraction. Unsupervised consensus clustering was performed 
with K = 2, as previously described (Monti et al., 2003), using the GenePat-
tern application (Gould et al., 2006). Genes differentially expressed between 
cluster I and cluster II adult T-ALL cases were identified using the Compara-
tive Marker Selection application in GenePattern (Gould et al., 2006) using 
a nonparametric P value calculation with 1,000 permutations.
A validation series of 30 previously reported adult T-ALL microarray 
data (Chiaretti et al., 2004) was normalized with GC-RMA using the open-
source Bioconductor project (www.bioconductor.org) within the statis-
tical programming language R (http://cran.r-project.org/). In this series, 
we selected the top 250 most variable probes from the unsupervised consen-
sus clustering analysis of the 57 ECOG T-ALL expression samples in our 
discovery series matched by gene names for consensus clustering as described 
in the previous paragraph. The relationship of clusters identified in the dis-
covery series and validation series was established by cross GSEA analysis 
(Subramanian et al., 2005) of the top up- and down-regulated genes 
(Student’s t test, P < 0.0001) in clusters I and cluster II of one series against 
the list of genes ranked by the t-score (cluster I vs. cluster II) in the other.
Enrichment of early immature/LYL1-positive, early cortical/TLX1, 
and late cortical/TAL1-associated genes in the gene expression clusters iden-
tified in our adult T-ALL series was analyzed by GSEA using the t test metric 
and 1,000 permutations of the genes. In addition, enrichment of myeloid- 
and lymphoid-associated genes was studied by a similar GSEA analysis using 
myeloid and lymphoid (Golub et al., 1999) gene sets. Similarly, we analyzed 
the relationship of the early immature adult T-ALL signature with that of 
different sorted human hematopoietic populations (Novershtern et al., 2011; 
Gene Expression Omnibus [GEO] accession no. GSE24759], the gene 
expression profiles generated for the specific populations of sorted human 
thymocytes, and gene sets associated with ETP T-ALL (Coustan-Smith 
et al., 2009), as described above. GEO accession nos. for adult T-ALL and 
normal thymocyte microarray data analyzed here are GSE33469 and 
GSE33470, respectively.
Microarray data from human T-ALL cell lines (Palomero et al., 2007; 
GEO accession no. GSE5682) were analyzed for their relationship with 
these mutant ETV6 alleles harbor dominant-negative activ-
ity. Consistently, supervised analysis of microarray gene 
expression signatures of ETV6 wild-type (n = 19) and ETV6-
mutated (n = 9) immature adult T cell leukemias showed that 
ETV6-mutated cases have a characteristic gene expression 
signature dominated by up-regulated transcripts (Fig. 4 F and 
Fig. S2), which included the myeloid marker CD33 and 
genes involved in leukemia development and stem cell 
homeostasis, such as HOXA13 (Su et al., 2006; Bach et al., 
2010), TP63 (Bernassola et al., 2005; Crum and McKeon, 
2010), PTEN (Yilmaz et al., 2006; Zhang et al., 2006), and 
PRDM16 (Du et al., 2005; Chuikov et al., 2010), which is a 
gene translocated to the ETV6 locus in AML (Duhoux et al., 
2011; Fig. 4 F). Notably, all ETV6 mutant T-ALL samples 
in our series were characteristically CD33 positive (5/5 [100%] 
immature ETV6 mutant T-ALLs vs. 11/24 [46%] immature 
ETV6 wild-type T-ALLs; P < 0.05; Table S3).
After these results, and to test the transcriptional effects of 
ETV6 inactivation in immature T-ALL, we analyzed the 
gene expression changes induced upon small interfering RNA 
(siRNA)-mediated knockdown of ETV6 in LOUCY cells, a 
T-ALL cell line with a transcriptional program highly related to 
that of immature T-ALLs (Fig. 5 A, Fig. S3). Notably, GSEA 
analysis of this ETV6 knockdown signature showed a signifi-
cant enrichment in genes that are characteristically up-regulated 
in ETV6 mutant immature T-ALLs, including HOXA13, 
PRDM16, PTEN, and CD33 (P = 0.016; Fig. 5 B).
Overall, our results demonstrate a high prevalence of early 
immature T-ALLs in adult T-ALL, which show increased 
heterogeneity in their immunophenotypes compared with 
pediatric ETP-TALLs, mixed lymphoid and myeloid charac-
teristics, and frequent truncating mutations in the ETV6 tumor 
suppressor gene.
MATERIALS AND METHODS
Patient samples and cell lines. Leukemic DNA and cryopreserved 
lymphoblast samples were provided by the Eastern Cooperative Oncology 
Group (ECOG). All samples were collected in clinical trials E2993 (Marks 
et al., 2009) and C10403. Informed consent to use leftover material for re-
search purposes was obtained from all the patients at trial entry according to 
the Declaration of Helsinki. T cell phenotype was confirmed by flow 
cytometry. In total, 82 adult T-ALL samples were used in this study, includ-
ing 57 samples used for the gene expression profiling study and mutation 
analysis and 25 additional cases used for mutation screening.
The LOUCY cell line was cultured in RPMI-1640 media supple-
mented with 10% fetal bovine serum, 100 U/ml penicillin G, and 100 µg/ml 
streptomycin at 37°C in a humidified atmosphere under 5% CO2. HEK293T 
cells were cultured under similar conditions in DME media.
Sorting of human thymocyte populations from human thymus. 
Thymus samples were obtained as surgical tissue discards from 3 pediatric 
patients (age from 7 d to 6 mo) undergoing cardiac surgery at the New York 
Presbyterian Hospital. Single-cell suspensions were prepared by dissecting 
the thymus into small pieces and passing the tissue through a cell strainer 
(diameter 70 m), and mononuclear cells were isolated by Ficoll density 
centrifugation (GE Healthcare). CD34+ human thymocyte populations were 
obtained by positive selection using magnetically activated cell sorting using 
the CD34 MicroBead kit (Miltenyi Biotec) and by negative selection using 
the CD3 MicroBead kit (Miltenyi Biotec). Magnetically isolated CD34+ cells 
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included in this study (n = 57). Table S2 shows an overview of the my-
eloid and T-lymphoid specific genetic alterations in adult T-AL. Table S3 
shows the immunophenotypic features of the ETV6 mutant adult T-ALL 
samples (n = 10). Table S4 shows the primer sequences used for ETV6 
mutations analysis. Online supplemental material is available at http://www 
.jem.org/cgi/content/full/jem.20112239/DC1.
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 Figure S1.  Independent validation of gene expression cluster in adult T-ALL. Consensus clustering analysis in a validation series of 30 adult T-ALL 
samples (top). Crossed GSEA of genes differentially expressed in clusters I and II identifi ed in the discovery and validation series (bottom). 
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 Figure S2.  ETV6 mutant gene signature in early immature adult T-ALL. Supervised analysis of  ETV6 mutant versus  ETV6 wild-type gene expres-
sion signatures in early immature adult T-ALLs (P < 0.001; FC>1.25). Genes signifi cantly up-regulated and down-regulated in  ETV6 mutant early immature 
adult T-ALLs are shown in a heatmap. The scale bar shows color-coded differential expression from the mean in standard deviation units, with red indi-
cating higher levels and blue lower levels of expression. 
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 Figure S3.  LOUCY is a T-ALL cell line with a transcriptional program highly related to early immature adult T-ALL. GSEA of transcripts signifi -
cantly up-regulated in early immature adult T-ALL in gene expression signatures obtained from a panel of T-ALL cell lines. Leading edge genes are shown 
in a heatmap of genes up-regulated in early immature  ETV6 mutant T-ALL that are most differentially expressed in between LOUCY and other T-ALL cell 
lines, including ALL-SIL, CCRF, CTV1, CUTLL1, DND41, HPB-ALL, KOPTK1, RPMI8402, and T-ALL-1. Genes in the heat map are shown in rows and each indi-
vidual sample is shown in one column. The scale bar shows color-coded differential expression from the mean in standard deviation units, with red indi-
cating higher levels and blue lower levels of expression. 
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 Table S1. Adult T-ALL immunophenotypes ( n = 57) 
ID TdT CD133 CD117 CD34 cCD3 CD5 mfi _CD5 CD1 CD7 CD2 CD3 TCR AB TCR GD CD4 CD8 CD33 CD13 CD11b
Cluster I 1 99 nt 0 99 99 0 1.1 0 99 99 0 0 0 0 0 99 99 99
Cluster I 2 99 0 0 99 96 99 51.5 0 99 99 99weak 0 0 0 0 0 99 0
Cluster I 3 14 30 0 99 99 99 11.0 0 99 0 0 0 0 0 0 99 0 99
Cluster I 4 99 0 0 0 99 99 25.4 99 99 99 0 1 0 99 99 0 0 0
Cluster I 5 99 0 98 99 99 99 4.0 0 99 0 0 0 0 0 0 99 0 99
Cluster I 6 99 99 99 99 99 0 1.1 0 99 99 0 0 0 0 0 0 99weak 99
Cluster I 7 99 0 0 0 99 99 22.6 99 99 99weak 0 0 0 99 99 0 0 0
Cluster I 8 99 95 99 99 99 99 9.3 0 99 0 0 0 0 0 0 95 95 99
Cluster I 9 7 0 99 0 97 0 5.9 0 99 0 99 0 0 0 0 0 99 0
Cluster I 10 99 0 0 55 97 0 1.0 0 99 0 0 0 0 0 0 99 0? 0
Cluster I 11 90 0 99 0 99 93 16.4 nt 99 0 0 0 0 0 0 0 99 0
Cluster I 12 97 99 0 99 99 99 4.1 0 99 99weak 0 0 0 0 0 99 99 99
Cluster I 13 nt 0 20 99 99 50 4.2 0 99 99weak 0 0 0 0 0 99weak 99weak 40
Cluster I 14 28 98 99 99 99 93 18.6 0 99 90 0 0 0 0 99 0 0 0
Cluster I 15 91 nt 99 99 99 0 1.9 0 98 99 0 0 0 0 0 99weak 99 95
Cluster I 16 94 99 99 99 99 0 1.1 0 99 44 0 0 0 0 0 0 99 98
Cluster I 17 99 0 0 0 99 99 18.2 0 99 0 0 0 0 0 0 0 99 0
Cluster I 18 30 95 0 99 99 99 10.7 0 99 0 99 0 0 0 0 99 99weak 99
Cluster I 19 99 97 99 98 99 0 1.2 0 99 99 0 0 0 0 0 0 98 20
Cluster I 20 15 99 40 20 99 0 1.7 0 99 0 0 0 0 0 0 99 0 90
Cluster I 21 99 99 0 99 99 95 6.7 0 99 99weak 0 0 0 29 0 99 95 90
Cluster I 22 20 0 95 99 99 99 4.1 0 98 0 0 0 0 0 95 96 95 0
Cluster I 23 20 95 0 99 99 99 11.1 0 99 0 0 0 0 0 0 99 99 0
Cluster I 24 99 90 56 99 99 99 13.1 0 99 99weak 0 0 0 0 0 99 99weak 99
Cluster I 25 99 0 99 0 99 0 1.7 0 99 0 99 0 0 0 99 0 99 0
Cluster I 26 nt nt 0 99 99 99 13.4 nt 99 99 0 nt nt nt nt 0 nt 0
Cluster I 27 99 99 0 99 99 99 12.7 0 99 0 0 0 0 0 0 99 99 99
Cluster I 28 0 0 0 0 99 0 1.1 0 99 0 0 0 0 99 0 0 0 0
Cluster I 29 0 99 20 99 99 99 4.3 0 99 0 0 99 0 0 0 99 0 99
ID TdT CD133 CD117 CD34 cCD3 CD5 mfi _CD5 CD1 CD7 CD2 CD3 TCR AB TCR GD CD4 CD8 CD33 CD13 CD11b
Cluster II 30 38 0 0 0 94 96 60.5 91 97 98 0 nt nt 95 98 0 0 0
Cluster II 31 60 nt 0 99 99 99 26.1 30 99 99 99 99 0 0 90 0 0 0
Cluster II 32 99 nt 0 0 81 96 1.9 45 97 92 95 3 0 77 90 42 0 15
Cluster II 33 89 0 0 0 99 99 28.5 99 99 99 99 0 0 99 99 0 0 0
Cluster II 34 98 0 0 99 99 99 4.2 0 99 40 0 0 0 0 99 0 99 0
Cluster II 35 99 0 0 20 99 99 29.3 0 99 99 99 0 0 99 99 99 0 0
Cluster II 36 96 0 0 0 99 99 48.8 99 99 99 0 0 0 99 99 0 0 0
Cluster II 37 99 0 0 0 99 99 32.1 99 99 99 0 0 0 99 99 0 0 0
Cluster II 38 99 0 0 0 99 99 17.6 99 99 0 55 99 0 0 0 99 99 0
Cluster II 39 99 0 0 0 99 99 6.7 0 99 0 0 0 0 99 99 0 0 0
Cluster II 40 99 99 0 99 99 99 30.4 0 99 30 0 0 0 0 99 0 99 99
Cluster II 41 99 0 0 99 99 99 16.5 0 99 70 99 0 99 0 75 0 99 0
Cluster II 42 99 0 0 30 99 99 29.5 99 99 99 0 0 0 95 60 0 30 0
Cluster II 43 99 0 0 nt 99 99 21.9 35 99 76 99 0 99 99 99 0 0 0
Cluster II 44 99 0 0 99 99 99 17.8 0 99 99 99 0 0 0 0 0 99 0
Cluster II 45 99 nt nt nt 99 99 23 99 99 99 0 0 0 99 99 0 0 0
Cluster II 46 99 0 0 0 99 99 28.6 99 99 99 40 0 0 99 99 0 99 0
Cluster II 47 92 0 0 99 99 99 8.5 0 99 99 99 0 0 99 99 0 99 0
Cluster II 48 99 0 0 0 99 99 18.0 99 98 99 0 0 0 99 99 0 0 0
Cluster II 49 96 0 0 99 97 95 5.1 0 94 94 0 0 0 99 99 0 0 0
Cluster II 50 99 0 0 99 99 99 8.9 0 99 99 0 0 0 0 99 0 98 99
Cluster II 51 99 0 0 99 99 95 32.7 0 99 99 0 0 0 0 99 0 99 0
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 Table S1. Adult T-ALL immunophenotypes ( n = 57) (Continued) 
ID TdT CD133 CD117 CD34 cCD3 CD5 mfi _CD5 CD1 CD7 CD2 CD3 TCR AB TCR GD CD4 CD8 CD33 CD13 CD11b
Cluster II 52 0 0 0 0 99 0 1.1 0 99 50 0 0 0 0 0 0 99 0
Cluster II 53 58 0 0 0 99 99 5.7 95 99 99 99 0 0 99 99 0 0 0
Cluster II 54 99 0 0 0 99 99 17.8 0 99 0 45 0 0 0 0 0 90 0
Cluster II 55 99 0 99 0 99 99 15.2 95 99 99 0 0 0 95 95 0 0 0
Cluster II 56 0 0 0 0 99 99 15.6 0 99 99 99 0 0 0 99 0 0 0
Cluster II 57 nt nt 0 0 99 99 31.3 nt 99 99 0 nt nt nt nt 0 nt 0
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 Table S2. Myeloid and T-lymphoid specifi c genetic alterations in adult T-ALL ( n = 57). 
Myleoid mutations T-ALL mutations
ID IDH1 IDH2 FLT3 NRAS DNMT3A NOTCH1 FBXW7 IL7R
Immature/Cluster I 1 0 0 0  1 0 0 0 0
Immature/Cluster I 2 0 0 0 0 0 0 0 0
Immature/Cluster I 3 0 0 0  1 0  1 0 0
Immature/Cluster I 4 0 0 0 0 0 0 0 0
Immature/Cluster I 5 0 0 0 0 0  1 0 0
Immature/Cluster I 6 0 0  1 0 0 0 0 0
Immature/Cluster I 7 0 0 0 0 0 0 0 0
Immature/Cluster I 8  1 0 0 0 0 0 0 0
Immature/Cluster I 9 0  1 0 0 0 0  1 0
Immature/Cluster I 10 0 0 0 0 0  1 0  1 
Immature/Cluster I 11 0 0 0 0 0 0 0 0
Immature/Cluster I 12 0  1 0 0  1  1 0 0
Immature/Cluster I 13 0  1 0  1 0  1 0 0
Immature/Cluster I 14 0 0 0 0 0 0 0 0
Immature/Cluster I 15 0 0  1 0 0 0 0 0
Immature/Cluster I 16 0 0  1 0 0 0 0 0
Immature/Cluster I 17 0 0 0 0 0 0 0 0
Immature/Cluster I 18 0 0 0 0 0  1 0 0
Immature/Cluster I 19 0 0 0 0 0 0 0 0
Immature/Cluster I 20 0 0 0  1 0 0 0 0
Immature/Cluster I 21 0 0 0 0 0 0 0 0
Immature/Cluster I 22 0 0  1 0 0  1 0 0
Immature/Cluster I 23 0 0 0 0 0 0 0 0
Immature/Cluster I 24 0 0 0 0 0  1 0 0
Immature/Cluster I 25 0 0 0 0  1  1 0 0
Immature/Cluster I 26 0 0 0 0 0  1 0 0
Immature/Cluster I 27 0 0 0  1 0  1 0 0
Immature/Cluster I 28 0 0 0 0 0 0 0 0
Immature/Cluster I 29 0 0  1 0 0 0 0 0
non-immature Cluster II 30 0 0 0 0 0  1 0 0
non-immature Cluster II 31 0 0 0 0 0 0 0 0
non-immature Cluster II 32 0 0 0 0 0  1 0 0
non-immature Cluster II 33 0 0 0 0 0  1  1 0
non-immature Cluster II 34 0 0 0 0 0 0 0 0
non-immature Cluster II 35 0 0 0 0 0  1 0  1 
non-immature Cluster II 36 0 0 0  1 0 0  1 0
non-immature Cluster II 37 0 0 0 0 0  1 0 0
non-immature Cluster II 38 0 0 0 0 0  1 0  1 
non-immature Cluster II 39 0 0 0 0 0  1 0  1 
non-immature Cluster II 40 0 0 0 0 0  1 0 0
non-immature Cluster II 41 0 0 0 0 0  1 0 0
non-immature Cluster II 42 0 0 0 0 0  1 0  1 
non-immature Cluster II 43 0 0 0 0 0 0  1  1 
non-immature Cluster II 44 0 0 0 0 0  1 0 0
non-immature Cluster II 45 0 0 0 0 0  1 0 0
non-immature Cluster II 46 0 0 0 0 0  1 0 0
non-immature Cluster II 47 0 0 0 0 0  1  1 0
non-immature Cluster II 48 0 0 0 0 0  1 0 0
non-immature Cluster II 49 0 0 0 0 0  1  1 0
non-immature Cluster II 50 0 0 0 0 0  1 0 0
non-immature Cluster II 51 0 0 0 0 0  1 0 0
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 Table S2. Myeloid and T-lymphoid specifi c genetic alterations in adult T-ALL ( n = 57). (Continued) 
Myleoid mutations T-ALL mutations
ID IDH1 IDH2 FLT3 NRAS DNMT3A NOTCH1 FBXW7 IL7R
non-immature Cluster II 52 0 0 0 0 0 0 0 0
non-immature Cluster II 53 0 0 0 0 0 1 0 1
non-immature Cluster II 54 0 0 0 0 0 1 0 0
non-immature Cluster II 55 0 0 0 0 0 1 0 0
non-immature Cluster II 56 0 0 0 0 0 0 0 0
non-immature Cluster II 57 0 0 0 0 0 0 0 0
 Table S3. ETV6 mutant adult T-ALL immunophenotypes ( n = 10) 
ID TdT CD117 CD34 CD13 CD33 CD10 CD11b cCD3 CD5 CD1 CD7 CD2 CD3 TCR AB TCR GD CD4 CD8
3 14 0 99 0 99 0 99 99 99weak 0 99 0 0 0 0 0 0
5 99 98 99 0 99 0 99 99 99weak 0 99 0 0 0 0 0 0
18 30 0 99 99weak 99 0 99 99 99 0 99 0 99 0 0 0 0
24 99 56 99 99weak 99 0 99 99 99 0 99 99weak 0 0 0 0 0
27  NA 0 99 99 99 0 99 99 99weak 0 99 0 0 0 0 0 0
58 99 0 36 0 99 0 62 99 99 0 92 25 0 NA NA 0 0
59 21 0 96 92 91 60 95 90 87 0 92 96 0 NA NA 0 0
60 99 0 99 99 99 99 99 99 99 0 99 99 0 0 0 0 0
61 89 0 99 99 99 84 98 99 0 0 99 0 0 0 0 0 0
62 99 0 80 99 99 99 99 99 99 0 99 99 0 0 0 0 0
 Table S4.  ETV6 PCR and sequencing primers. 
Primer Sequence
Exon 1 Forward 5  -GGGGAGAGATGCTGGAAGAAA-3  
Exon 1 Reverse 5  -TTTCATTGTCAAAAAGCAAGG-3  
Exon 2 Forward 5  -CCGAGATGGTCTCATACCTCC-3  
Exon 2 Reverse 5  -TGAGAAACAAGGAACAGGAACC-3  
Exon 3 Forward 5  -GACCTTCTCCCTTTATTCCAGC-3  
Exon 3 Reverse 5  -TCCTTCAACTTCCTTCCATCG-3  
Exon 4 Forward 5  -TGCGCTCCAATTGTATCTTTG-3  
Exon 4 Reverse 5  -TGAGCTTCAGGGAACCAAGAG-3  
Exon 5 Forward 5  -TCCTCCATTTACCGCCTGTAG-3  
Exon 5 Reverse 5  -CTAATTGGGAATGGTGCGAG-3  
Exon 6 Forward 5  -CAAGCTAGGCAGAAGCAGTTG-3  
Exon 6 Reverse 5  -ACGATTATCCTCCAATCCAGG-3  
Exon 7 Forward 5  -TAATAGCTCCCGCAGTGCC-3  
Exon 7 Reverse 5  -TGTAGCAATGATTGGCTTTGG-3  
Exon 8 Forward 5  -GGGTTCAGTAGCTCTCCAGC-3  
Exon 8 Reverse 5-‘TCTGCAAGAGAAGTGTCCCTG-3  
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